uniQure (NASDAQ:QURE) Stock Price Up 7.2% – Here’s Why

uniQure N.V. (NASDAQ:QURE) shares traded up 7.2% on Wednesday . The stock traded as high as $28.72 and last traded at $28.69. 716,792 shares were traded during trading, a decline of 73% from the average session volume of 2,658,588 shares. The stock had previously closed at $26.76.

Analysts Set New Price Targets

Several equities research analysts have weighed in on QURE shares. The Goldman Sachs Group upped their target price on uniQure from $9.00 to $10.00 and gave the stock a “neutral” rating in a research note on Monday, April 20th. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $12.00 to $35.00 in a research note on Wednesday, March 11th. Barclays cut their target price on uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a research note on Monday, March 23rd. TD Cowen restated a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Finally, Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $42.83.

uniQure Stock Up 4.2%

The company has a market capitalization of $1.76 billion, a P/E ratio of -8.01 and a beta of 0.98. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a 50 day moving average price of $20.44 and a 200 day moving average price of $21.87.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The company had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. On average, research analysts anticipate that uniQure N.V. will post -3.68 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In related news, insider Walid Abi-Saab sold 45,000 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $25.06, for a total value of $1,127,700.00. Following the completion of the transaction, the insider owned 169,669 shares in the company, valued at $4,251,905.14. This trade represents a 20.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.65% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Flax Pond Capital LLC raised its holdings in uniQure by 3.8% in the 1st quarter. Flax Pond Capital LLC now owns 152,031 shares of the biotechnology company’s stock valued at $2,486,000 after buying an additional 5,533 shares during the last quarter. Stempoint Capital LP raised its position in uniQure by 79.5% during the 1st quarter. Stempoint Capital LP now owns 78,066 shares of the biotechnology company’s stock worth $1,276,000 after purchasing an additional 34,581 shares during the last quarter. Irenic Capital Management LP bought a new position in uniQure during the 1st quarter worth $1,635,000. Readystate Asset Management LP raised its position in uniQure by 39.6% during the 1st quarter. Readystate Asset Management LP now owns 504,702 shares of the biotechnology company’s stock worth $8,252,000 after purchasing an additional 143,142 shares during the last quarter. Finally, Royal Bank of Canada raised its position in uniQure by 26.0% during the 1st quarter. Royal Bank of Canada now owns 107,888 shares of the biotechnology company’s stock worth $1,763,000 after purchasing an additional 22,248 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.